RECRUITING

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).

Official Title

A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)

Quick Facts

Study Start:2025-03-12
Study Completion:2028-01-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06792695

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 130 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Histopathologically confirmed colorectal adenocarcinoma.
  2. * Provision of FFPE tumor sample collected as per SoC.
  3. * Presence of measurable disease by RECIST 1.1 criteria.
  4. * ECOG performance status of 0 or 1.
  5. * Life expectancy ≥ 12 weeks at the time of screening.
  1. * Central nervous system metastases or spinal cord compression
  2. * Known history of severe allergy to any monoclonal antibody or study intervention.
  3. * Any unresolved toxicity CTCAE Grade ≥ 2 from a previous anticancer therapy.
  4. * History of another primary malignancy.

Contacts and Locations

Study Contact

AstraZeneca Clinical Study Information Center
CONTACT
1-877-240-9479
information.center@astrazeneca.com

Study Locations (Sites)

Research Site
Scottsdale, Arizona, 85259
United States
Research Site
Los Angeles, California, 90089
United States
Research Site
Washington, District of Columbia, 20007
United States
Research Site
Chicago, Illinois, 60637
United States
Research Site
Baltimore, Maryland, 21224
United States
Research Site
Boston, Massachusetts, 02114
United States
Research Site
Rochester, Minnesota, 55905
United States
Research Site
Rochester, New York, 14618
United States
Research Site
Cleveland, Ohio, 44106
United States
Research Site
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: AstraZeneca

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-12
Study Completion Date2028-01-12

Study Record Updates

Study Start Date2025-03-12
Study Completion Date2028-01-12

Terms related to this study

Keywords Provided by Researchers

  • Metastatic disease
  • Immunotherapy
  • Liver metastasis
  • Mismatch-repair-proficient
  • Antibody targeting
  • Colorectal Cancer
  • CANTOR

Additional Relevant MeSH Terms

  • Metastatic Colorectal Cancer